A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

导出 LinkOut

翻译打印收藏纠错

第一作者： David A,Bond

第一单位： Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical Oncology.

作者： David A,Bond ^[1] ; Ying,Huang ^[1] ; Beth A,Christian ^[1] ; Samantha,Jaglowski ^[1] ; Don,Benson ^[1] ; Lapo,Alinari ^[1] ; Robert A,Baiocchi ^[1] ; Jonathon B,Cohen ^[2] ; Kristie A,Blum ^[1] ; Kami J,Maddocks ^[2]

作者单位： Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical Oncology. ^[1] Emory University, Atlanta, GA, USA. ^[2]

主题词氨基吡啶类(Aminopyridines);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);人类(Humans);淋巴瘤, 非霍奇金(Lymphoma, Non-Hodgkin);吗啉类(Morpholines)

DOI 10.1080/10428194.2022.2034154

PMID 35129029

发布时间 2022-07-26

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交